LCV2 control
(Plasmid
#217443)
-
Purpose(Empty Backbone) Lentiviral vector expressing Cas9 without a targeting sgRNA
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 217443 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonelentiCRISPRv2
-
Vector typeMammalian Expression, Lentiviral, CRISPR
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)NEB Stable
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameNone
Resource Information
-
Supplemental Documents
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
LCV2 control was a gift from Jarrod Johnson (Addgene plasmid # 217443 ; http://n2t.net/addgene:217443 ; RRID:Addgene_217443) -
For your References section:
Cell-free assays reveal that the HIV-1 capsid protects reverse transcripts from cGAS immune sensing. Scott TM, Arnold LM, Powers JA, McCann DA, Rowe AB, Christensen DE, Pereira MJ, Zhou W, Torrez RM, Iwasa JH, Kranzusch PJ, Sundquist WI, Johnson JS. PLoS Pathog. 2025 Jan 28;21(1):e1012206. doi: 10.1371/journal.ppat.1012206. 10.1371/journal.ppat.1012206 PubMed 39874383